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ABSTRACT 
In this study we identified and characterized a novel cyclic peptide that facilitates the rapid 
transportation of conjugated molecules across the epithelial layer of the small intestine. The 
peptide was initially selected from phage display libraries using a large animal experimental model 
which employed consecutive in vitro and in vivo panning. The procedure was designed to enrich 
for peptides that facilitated transcytosis across the intestinal epithelium into the intestinal afferent 
lymphatic system. A small set of peptides was repeatedly isolated using this selection method, 
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however the cyclic nonamer CTANSSAQC, 13C dominated. The activity of the putative targeting 
peptide C13 was then verified using a mouse model.  
These experiments showed that the 13C peptide as well as macromolecules conjugated to it were 
rapidly transported across the intestinal mucosa into distinct subsets of epithelial cells and CD11+ 
cells located in the lamina propria and Peyer’s Patches. Significant amounts of intact protein could 
be delivered into the systemic circulation after rectal and nasal application. Thus, peptide 13C is 
regarded as an attractive carrier candidate for mucosal delivery of large molecules. The preferential 
targeting to distinct intestinal cells may be utilized to deliver active biological drugs for the 
effective control of diseases of the gut. 
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INTRODUCTION 
While most diseases including inflammatory diseases or tumors are localized and display tissue-
specific features, drugs to combat these diseases are usually applied via systemic routes. This 
implies a potential loss of treatment selectivity and efficacy. Similarly, vaccines elicit 
quantitatively and qualitatively different immune responses depending on the route of 
application. For example, gastrointestinal administration of proteins, in the absence of adjuvants, 
preferentially induces immunological tolerance ("oral tolerance")1, but adjuvant-including enteric 
vaccines are superior in inducing IgA responses which are important to prevent infections with 
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gastrointestinal pathogens. However, targeting delivery of effective vaccines into the immune-
inductive sites of the intestine remains a significant challenge for the pharmaceutical industry.  
Novel delivery of drugs via the gastrointestinal tract or airways is convenient for patients, 
although to date not efficient for non-permeating agents, notably protein based biologics or 
vaccines. The efficiency of mucosal delivery is compromised by potential degradation of 
proteins and peptides in the gastrointestinal tract, by the thickness of the mucus layer as well as 
by the low transport capacity of epithelial cells for uncleaved macromolecules. New treatments 
that enable tissue-specific delivery of bioactive agents would therefore offer significant benefits 
compared to systemic delivery. The aim of the present study was to develop a new delivery 
vehicle that would facilitate the rapid transportation of macromolecular agents upon mucosal 
administration. 
The epithelial layer is composed of epithelial cells connected by tight junctions. It functions as a 
physical barrier that prevents environmental agents from penetrating into host tissue. The 
intestinal epithelium facilitates the directed transport of nutrients, ions, lipids and, to some 
degree, also macromolecules. In addition, specialized cells in the epithelial layer overlaying 
Peyer´s patches (PP) and isolated lymphoid follicles, the M (microfold) cells, are known for their 
high uptake capacity for luminal antigens and even particulate matter2, 3. Moreover, recent 
studies have shown that goblet cells, besides their known capacity to secret mucins, are able to 
sample peptides from the lumen of the small intestine4. 
Phage display technology has been widely used for in vitro and in vivo screening of tissue 
specific markers and peptides5. The method has been successfully employed to dissect biological 
processes, such as homing to vascular tissue in tumors6-9, cancer metastasis8, 10-12, synovial 
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targeting13-15 and receptor identification16, 17. Extensive screening of phage display libraries has 
also been used to identify ligands that facilitate translocation across the mucosa of the 
gastrointestinal tract18 or binding to and transport via M cells19, 20 or goblet cells21, 22.  
The aim of this study was to identify and characterize novel peptides that are actively transcytosed 
via the intestinal mucosa. These peptides were selected from phage display libraries by consecutive 
in vitro and in vivo panning using a large animal experimental model. The selection method led to 
the identification of the cyclic nonamer CTANSSAQC (13C) peptide. The activity of this putative 
targeting peptide was then verified using a mouse model. We found that 13C as well as 13C-
conjugated macromolecules were rapidly transcytosed via the intestinal mucosa in both sheep and 
mouse models. Peptide-protein conjugates were taken up by, and enriched in, both epithelial and 
dendritic cells located in the lamina propria and PP and additionally delivered into systemic 
circulation via the lymph. Thus, peptide 13C is regarded as an attractive carrier candidate for the 




1. Animals.  
All sheep experiments were conducted under the approval of the Animal Ethics Committee of 
the Wallaceville Animal Research Centre, New Zealand. 
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All mice experiments were performed in accordance with the European directive on the 
protection of animals used for scientific purposes and the respective German animal welfare 
legislation. Female BALB/c mice were purchased from Charles River and used at 8 to 10 weeks 
of age. Mice were maintained under specific pathogen free conditions and randomly assigned to 
the different experimental groups.  
2. Phage libraries.  
The cyclic Ph.D.-C7CTM and linear Ph.D.-12TM libraries were purchased from New England 
Biolabs (Beverly, MD). They are based on a combinatorial library of random peptides fused to a 
minor coat protein (pIII) of M13 phage displaying either a cyclic or linear peptide at up to 5 
copies per phage. Each library consists of 1.28x109 possible residue sequences, and yields 
approximately 200 copies of each sequence per 10 µl of phage.  
3. Panning procedures 
3.1.  In vitro binding of phage to sheep intestine 
For selection of phage binding in vitro to sheep tissue, both libraries were panned independently. 
A 10 cm segment of the jejunum, including a PP, was removed from sheep at necropsy, washed 
with PBS and tied off at both ends. The lumen was partly filled with 10 µl of an aliquot of a 
phage display library diluted in 5 ml of PBS supplemented with a complete protease inhibitor 
cocktail (Roche, Basel, Switzerland). The segment was incubated 30 min slowly rocking on ice. 
The content was then discarded and an approximately 3 cm segment containing a PP isolated. 
This segment was cut open on the minor curvature, repeatedly washed with cold PBS and 
transferred to an E. coli K91/Kan culture growing at the mid-log phase at an OD600 of 0.5 to 
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enable tissue associated phage to infect the bacteria. After 30 min, tissue was discarded and 
aliquot samples were taken for phage titering, while the remainder was amplified for 4.5 h at 37 
°C. Amplified phage were purified by PEG/NaCl precipitation, washed in PBS and titered using 
standard protocols.  The amplified phage were then subjected to a similar second selection 
procedure using freshly prepared tissue. PP tissue was isolated and washed >10 times in cold 
PBS / 5mM EDTA prior to recovery of phage.  
3.2.  In vivo binding of phage to sheep intestine and PP 
For in vivo panning, phage preselected by in vitro panning were amplified and further 
independently subjected to an in vivo panning procedure in sheep. For all in vivo panning 
experiments input phage were supplemented with complete protease inhibitor and chloroquine 
(500 mg) was injected i.m. to temporarily inhibit the processing of antigens within antigen 
presenting cells23. Three approximately 30 cm long intestinal segments containing at least one PP 
were accessed by laparotomy of an anaesthetized sheep. The ingesta were flushed out by 
injection of 20 ml of water and the ends clamped off. An aliquot of amplified in vitro pre-
selected phage library diluted in 5 ml PBS was injected into loops for 15, 30 or 60 min. The 
animal was euthanized by barbiturate overdose (sodium pentobarbitone 125 mg/kg), intestinal 
segments removed, flushed with PBS / 5mM EDTA and rinsed several times with 0.2M glycine 
pH 2.2. Glycine-washes were used to remove any mucus, or mucus- and epithelium- bound 
phage from the tissue.  PP tissue was isolated from each of the washed segments, washed again 
repeatedly in glycine, processed by dissection into small pieces and partly solubilized in PBS 1% 
CHAPS prior to incubation in E. coli and phage titering and amplification of phage as above.   
3.3.  Recovery of phage from sheep intestinal lymph and PP 
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Amplified phage were pooled across sampling time points but pools derived from the cyclic or 
linear phage library were independently subjected to one modified in vivo selection procedure, 
where transcytosed phage were recovered from afferent lymph of sheep via lymphatic 
cannulation24, 25. The drainage of afferent lymph was visualized by injection of trypan blue into 
the sub-serosa of the intestine, and a pseudo-afferent lymph vessel was cannulated by insertion 
of a small catheter. Up to three approximately 30 cm segments of the intestine with at least one 
PP in the drainage region of the catheter were prepared followed by luminal challenge with an 
aliquot of pre-selected amplified phage as above. Lymph was collected continuously for up to 6 
h after challenge, into ice-cooled collection tubes containing heparin as an anti-coagulant. The 
animals were then euthanized and intestinal segments removed, PP tissue isolated and processed 
as above. Cells were separated from lymph plasma by centrifugation, solubilized in PBS/1% 
CHAPS and individual samples, including a pooled lymph sample, used to infect the E. coli host 
strain. Elution samples were taken after 30 min for titering, while the remaining phage were 
amplified as above.  
All samples derived from cyclic and linear phage libraries were then pooled and subjected to two 
additional in vivo selection procedures in sheep fitted with an afferent lymphatic cannula as 
above. 
3.4.  In vivo validation for specificity of the selected peptide phage 
To test whether the peptides selected for the ability to promote phage transcytosis were indeed 
preferentially transcytosed from the intestinal lumen into the lymphatic system of sheep, six 
clones that were identified in previous experiments (2L, 4L, 13C, 26PP, 28PP and 38PP) were 
individually amplified and then combined in equal amounts. An aliquot of this phage pool 
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consisting of approximately 5x1010 pfu was mixed with approximately 1x1015 pfu wild type 
phage (2x104 fold excess) to assess non-specific uptake. The phage pool was injected into an 
intestinal segment and tested for recovery of transcytosed phage via afferent lymphatic 
cannulation as above. Phage were isolated from lymphatic cells and lymph plasma 30 min and 2 
h post-injection. Peptide displaying phage were colorimetrically distinguished from wild type 
phage based on expression of β-galactosidase.  
4. Identification of individual phage clones.  
Samples were titered on LB/IPTG/Xgal plates that enabled differentiation between wild type 
and library phage plaques using the E. coli strain K91/Kan/BK in the standard procedure 
recommended by New England Biolabs. Individual library phage plaques were picked from 
elution samples (details are given in Tables 1 and 3), re-amplified and subjected to M13 phage 
DNA extraction using a commercially available kit (Qiagen, Venlo, Netherlands). DNA was 
sequenced using the 96gIII sequencing primer as recommended by New England Biolabs and a 
bioinformatics analysis performed using a basic BLAST search (BLASTp).  
5. Synthetic peptides and coupling procedures.  
For sheep experiments, a selection of the identified peptides (2L (CPTSHHRAC), 13C 
(CTANSSAQC), 28PP (CDPSPSRHC) and two versions of a scrambled 13C peptide (13Csc 
(CSNAQATSC or CASQNSTAC), which served as controls) were synthesized with a purity of 
>90%. Peptides were modified to enable radiolabelling and precipitation by C-terminal tyrosine 
and an N-terminal Biotin extension (AnaSpec, San Jose, CA). Spacers (LC and PEG4) were 
included to provide separation of the extensions from the peptide molecule. Radiolabelling with 
125I was performed by the chloramine T method26. To test for efficiency of radiolabelling of 
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peptides 5 µl of radioactively labelled peptide was diluted in 200 µl PBS, mixed with 50 µl of 
streptavidin agarose (SIGMA), incubated for 10 min on ice, pelleted and washed prior to 
measuring radioactivity with a gamma counter. Approximately 70% of radioactivity seen in the 
original sample was found in the precipitate, demonstrating that 70% of the radioactivity was 
peptide related.  
For mouse experiments, 13C and 13Csc peptide conjugates were either purchased from JPT 
Peptide Technologies (Berlin, Germany) or synthesized in house (for details see Supplementary 
Table 1). Briefly, solid phase peptide synthesis (SPPS) was performed on a 50 µM scale using a 
peptide synthesizer (Intavis, MultiPep RS) and a standard Fmoc/t-Bu  protocol, comprising 
double coupling at every cycle. The synthesis of the peptides was performed in plastic syringes 
at room temperature on a TentaGel S Ram resin (RappPolymere, Tübingen, Germany). 
Couplings were achieved by reacting four equivalents Fmoc-AA-OH with four equivalents 
PyBOP and eight equivalents N-Methylmorpholin (NMM) in Dimethylformamid (DMF). Biotin 
was coupled using the same conditions. A solution of 20% Piperidine in DMF was used to 
remove the Fmoc protection group. Peptides were deprotected and cleaved from the resin using a 
mixture of 10 mL Trifluoroacetic acid (TFA), 0.75 g phenol, 0.5 mL water, 0.5 mL 
methylphenylsulfide, and 0.25 mL 1,2-ethandithiol. After 3 h at room temperature, the cleavage 
solution was collected and the crude peptides were precipitated from ice-cold tert-Butyl-methyl 
ether. Crude peptides were washed five times with dry diethyl ether. Final Reverse Phase High 
Performance Liquid Chromatography (RP-HPLC; Waters, Eschborn, Germany) purification and 
analysis were achieved using a linear solvent gradient (eluent A: 0.05% TFA in water; eluent B: 
0.05% TFA in acetonitrile; linear gradient from 5 to 60% B over 30 min at a flow rate of 20 
ml•min-1, RT) over a Vydac C18 column (Hesperia, CA, US) and detection at 214 nm. Identities 
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of peptides were validated by MALDI-TOF mass spectrometry (VoyagerLT, Applied 
Biosystems, Weiterstadt, Germany). For immunohistochemical analysis of peptide uptake, the 
peptides were labeled with fluoresceinisothiocyanate (FITC). Full analysis and characterization 
of the peptides is provided in the supporting information (Supplementary Table 1; 
Supplementary Figures 2-6). 
For analysis of protein uptake in mice, several different streptavidin conjugates were prepared. 
Biotinylated peptide was added in a 10-fold excess to streptavidin solution and incubated at room 
temperature for one hour. The peptide-streptavidin conjugate was then purified by size exclusion 
using a PD Spintrap G25 column (GE Healthcare, Chalfont St Giles, UK). Conjugates with 
Alexa Fluor®488 and Alexa Fluor®546 coupled streptavidin (Jackson Immuno Research 
Laboratories, Inc., West Grove, PA) were used for in vivo visualization of protein uptake in 
mouse intestine and radiolabeled [I-125]-streptavidin (PerkinElmer, Inc., Waltham, MA) was 
used for in vivo analysis of transcytosis of peptide-protein constructs in mice. 
6. Analysis of peptide transcytosis in sheep.  
Afferent intestinal lymphatic cannulation was performed in sheep as described previously 24. 
Sheep were additionally fitted with a catheter (inner diameter 1.2 mm) that reached into the 
lumen of the jejunum and was anchored into the intestinal wall and exteriorised through the same 
abdominal opening as the lymphatic cannula. The intestinal catheter was placed in a part of the 
jejunum from which lymph was likely to drain into the cannulated lymphatic vessel, although 
lymph draining from other sites could not be excluded. After full recovery from surgery, 50 µg 
of radiolabelled peptide in 5 ml PBS supplemented with complete protease inhibitor was 
administered directly into the intestinal lumen. Peptides 13C, 28PP, 2L and 13Csc were 
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administered consecutively, every third or fourth day once radioactivity had declined to near 
background levels depending on how long the lymphatic cannula remained patent. Each peptide 
was given to 3 – 4 different animals (details are given in Supplementary Figure 1). Lymph was 
collected continuously and sampled for 30min prior to application, then at time points 30min, 1h, 
2h, 3h, 4h and 6h after administration. Radioactivity was measured at all collection time points in 
100 µl whole lymph, cells from 1 ml of lymph washed once in PBS, 100 µl of lymph plasma and 
streptavidin precipitate of 1 ml lymph plasma. During the experiment it became obvious that 
radioactivity was lost during cell washing and consequently measuring the activity of cells 
separated from 1 ml lymph was included. 
Intact biotin-tagged radioactive peptide was precipitated from lymph plasma using streptavidin 
agarose (SIGMA, St. Louis, MO). Lymph plasma was obtained by centrifugation of whole 
lymph for 5 min at 400 g. Streptavidin agarose was washed in PBS immediately prior to use, 
then 100 µl mixed with 1ml of lymph plasma, incubated for 30 min on ice, pelleted and washed 
before measuring radioactivity with a gamma counter. 
7. Visualization of peptide and protein uptake in mouse intestine.  
For in vivo visualization, BALB/c mice were anesthetized by i.p. injection of 
Ketamine/Xylazine (10 mg/kg / 200 mg/kg). The abdominal cavity was then opened by a 1cm 
midline incision and a segment of the intestine (approximately 2cm) containing at least one PP 
was located and tied off with surgical nylon. 150 µl peptide-construct solution was injected into 
the isolated segment, the intestine was placed back into the abdominal cavity and the wound 
closed. To analyze receptor saturation, unlabeled 13C was first injected into the isolated segment 
in a 10-fold excess and incubated for 10 min before subsequent injection of 13C-FITC. Mice 
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were sacrificed by cervical dislocation 5-45 minutes later, the isolated segment removed and 
flushed twice with PBS. The tissue was fixed in 2% PFA solution for approximately 16 h. Tissue 
was dehydrated by incubation in solutions of increasing sucrose concentrations starting with 
10%, 20% and finally 30%, each for 8-16 h at 4°C. After embedding the tissue in Tissue-Tec 
OTC cryo embedding medium and freezing, cryostat sections of 7 µm were cut using the HM 
560 Cryotome (Thermo Fischer Scientific, Waltham, MO). Slides were frozen at -20°C until 
further use.  
For immunohistochemical staining, the sections were warmed up to room temperature and 
rehydrated in PBS. All washing steps were performed using PBS containing 1% BSA and 0.1% 
Tween20 (SIGMA). Blocking buffer additionally contained 10% rat serum. After 20 min 
incubation with blocking buffer, the sections were stained with anti-CD11c mAb (N418; 
produced in-house) conjugated Alexa to Fluor®647 for 1 h at room temperature and washed 
twice. After staining, the slices were mounted with DAKO mounting medium containing DAPI 
(SIGMA). To examine the staining, a LSM 710 confocal microscope (Carl Zeiss, Jena, 
Germany) was used and photomicrographs were taken using the software Zen 2011 (Carl Zeiss 
MicroImaging GmbH, Göttingen, Germany).  
8. Analysis of transcytosis of peptide-protein constructs.  
Balb/c mice were dosed orally, rectally or nasally with radiolabelled peptide-streptavidin-[I-
125] constructs. For oral dosing, mice were gavaged with 0.5 mg in 200 µl PBS using a feeding 
needle. For rectal dosing, mice were injected rectally with 0.5 mg in 200 µl PBS using an 
umbilical catheter with a diameter of 0.5 x 0.8 mm that was introduced into the rectum. For nasal 
dosing mice were anesthetized with dexdomitor (0.4 mg/ml, Pfizer, New York City, NY) and 
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isoflurane (Forene®, Abbott, Chicago, IL) inhalation. After intra-nasal application of 0.05 mg 
construct in 20 µl PBS, mice were injected with anti-mepazole (2 mg/ml, Pfizer). After 4 h 
incubation with the peptide-streptavidin construct the mice were sacrificed, blood, urine and 
various organs (thymus, stomach, small intestine, large intestine, lung, liver, kidneys, heart and 
skin including the fur) were sampled. Blood cells were obtained by centrifugation, blood plasma 
was treated with Trichloroacetic acid (TCA) to separate degraded protein or free radioactivity 
from intact labeled protein (TCA-soluble plasma fraction). Radioactivity in the blood 
compartments was computed for a total blood volume of 1.5 ml per mouse (60 ml/kg). All 
samples were analyzed using a gamma counter (Wallac, Turku, Finland). 
9. Statistical analysis.  
Mixed modelling was used for data analysis of peptide transcytosis in sheep, with individual 
animals specified as random effects and peptides as fixed effects, using the REML (Residual 
Maximum Likelihood) criterion. The data consisted of LOGe AUC (area underneath curves over 
time) corrected for the value at hour 0 as a covariate, testing for differences between the four 
peptides. Values for streptavidin precipitated lymph samples were included in the analysis. Data 
were described as LOGeMeans (the mean of the LOGe AUC for each peptide, SE, minimum and 
maximum. Statistically significant differences were observed at p<0.05.  
Data of protein transport in mice are presented as means ± SEM. Significance was determined 
with unpaired student’s t test after confirming normality distribution by D’Agostino & Pearson 
omnibus normality test. Differences were considered as statistically significant with p≤0.05 (*), 




1. Selection for peptides promoting intestinal transcytosis of phage  
For the in vitro selection procedures of Ph.D.-C7CTM and Ph.D.-12TM peptide display phage 
libraries, the numbers of input and recovered phage typically were >1012 pfu and >106 pfu/ml, 
respectively. The in vivo selection of peptides that promote binding of phage to PP, with 
amplified in vitro preselected phage (~1013 pfu) resulted in the recovery of >106 pfu/ml phage 
from PP tissue following a stringent low pH washing procedure.  
The first selection procedure for peptides that facilitate transcytosis from the lumen of intestinal 
segments into the draining lymph with amplified preselected phage (~1013 pfu) resulted in the 
recovery of typically >104 and occasionally >106 pfu/ml from PP tissue, lymph plasma and 
leukocytes recirculating in lymph.  
Two additional panning procedures involving afferent lymphatic cannulation with amplified  
preselected phage pooled across compartment origin and the collection time points resulted in an 
increase in recovered phage. The titer of phage recovered from PP was 106-107 pfu/ml, from the 
lymph pool 105–106 pfu/ml, and from the lymphatic cells 104–106 pfu/ml over the first two hours 
of sampling, with little recovery at the later sampling time points.  
Table 1. Identification of phage clones recovered via afferent lymphatic cannulation after the 
final two rounds of in vivo selection. Library origin, peptide sequence of individual phage clones 
and frequency of isolations in the respective tissue are shown. Over-represented amino acids H, 
P and S are highlighted in bold. 
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Frequency of isolations 
(n=33) 
Frequency of isolations 
(n=31) 
   Lymph cells PP Lymph cells PP 
2L C7CTM CPTSHHRAC 3 0 0 8 0 0 
4L C7CTM CKQPSHSAC 3 0 0 2 0 0 
13C C7CTM CTANSSAQC 0 2 6 2 12 0 
26PP 12TM STVMDSAVIVKS 0 0 0 0 0 8 
28PP C7CTM CDPSPSRHC 0 0 0 0 0 1 
38PP 12TM CKSAITPGSPSI 0 16 0 0 0 0 
70PP C7CTM CLHTHSLHC 0 0 1 0 0 0 
71PP 12TM VTKQGVHVGLPR 0 0 1 0 0 0 
73PP C7CTM CMQPGNILC 0 0 1 0 0 0 
 
More than 30 individual phage clones recovered from the three different compartments were 
subjected to sequencing following each of the final two in vivo transcytosis enrichment cycles. 
As shown in Table 1, only nine different peptides were found to be displayed on the selected 
phage because several peptides were represented in multiple clones. Three of the peptides, 2L, 
4L and 13C were found following both rounds of transcytosis enrichment, usually in the same 
compartment. Bioinformatics analysis of the nine peptides for homologues found no compelling 
matches in protein databases containing non-redundant protein sequences. Analysis of the 
frequency of amino acids in different positions revealed that their distribution was not random. 
Constraint peptides tended to have an over-representation of H, S and P but E, F, W, Y and V 
were not present.   
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2. In vivo validation for specificity of the selected peptide phage 
Preferential transcytosis of selected library phage was assessed in the presence of a 2x104 fold 
excess of wild type phage in an afferent cannulation experiment. Phage were isolated from 
lymphatic cells (~105 pfu) and lymph plasma (~106 pfu). Between 1% and 40% of phage 
recovered from the three compartments at 30 min and 2 h post-injection were non-wild type, 
demonstrating an approximately 102-104 fold enrichment of putative transcytosis peptide-
displaying phage compared to wild type phage (Table 2). Much greater enrichment was observed 
at the 30 minute as compared to the 2 hour time point, further suggesting that the peptide-
displaying phage were entering by a facilitated transcytosis process.  
Table 2. Recovery of phage from intestinal lymph after challenge with selected library phage 
clones in the presence of 2x104 fold excess of wild type phage. An approximately 102-104 fold 










lymph plasma 30x106 200x106 3x103 fold 
lymphatic cells 40x105 100x105 8x103 fold 
2h 
lymph plasma 4x106 200x106 4x102 fold 
lymphatic cells 1x105 100x105 2x102 fold 
 
Sequence analysis was performed to determine the relative abundance of phage displaying the 
six different putative transcytosis peptides obtained from the three compartments following in 
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vivo selection (Table 3). Two cyclic displayed peptides dominated the selection, 13C and 28PP, 
representing 36 of 40 clones sequenced.  
Table 3. Identification and frequency of library phage clones from intestinal lymph of sheep 
given a selection of library phage clones in the presence of 2x104 fold excess of wild type phage. 
A strong selection for clones 13C and 28PP was found.  
 Frequency of isolations 
compartment lymph cells 
time of isolation 0.5 h 2h 4h 0.5 h 2h 4h 
2L 0 1 1 0 0 0 
4L 0 0 0 0 0 0 
13C 9 2 2 10 0 1 
26PP 0 0 1 0 0 1 
28PP 1 2 2 7 0 0 
38PP 0 0 0 0 0 0 
 
3. Verification of peptide facilitated transcytosis from the intestine into lymph 
Peptides 2L, 13C, 28PP and a scrambled version of 13C (13Csc) were tested for translocation 
from the intestinal lumen into the draining lymph. Overall, the highest level of peptide was found 
in the lymph at either 30 min or 1 h after administration, followed by a decline to around base 
line levels by 6 to 24 h. REML variance components analysis of LOGe AUC (area underneath 
curve as defined by cpm vs. time) revealed significant differences between levels of peptides 
transcytosed into lymph plasma (p=0.019). Peptide 13C and to a lesser extent peptide 28PP, but 
little or no 2L and 13Csc peptide (control peptide), were transcytosed into the lymphatic system 
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of the intestine (LOGeMeans for peptides; 13C: 8.255; 2L: 5.677; 28PP: 6.717; and 13Csc: 
5.237; SE: 0.683 (max 0.7429; min 0.6241)) (Figure 1, and Supplementary Figure 1). 
Transcytosis of intact peptide 13C was higher than for 2L and 13Csc (p≤0.001), and 28PP was 
higher than for scrambled 13C (p=0.027) as determined by REML analysis. In summary, 13C 
peptide and, to a lesser extent, 28PP peptide display enhanced transcytosis from the lumen of the 
gut into the lymphatic system in a sheep model.  
 
Figure 1. Increased transcytosis of peptides 13C and to a lesser extent of 28PP into intestinal 
lymph plasma. Data represent the AUC (area underneath curve) of recovered radioactivity 
(cmp/ml lymph) (n=4 for peptides 2L, 13C and 28PP; n=3 for scrambled peptide 13C). p<0.05 
between treatments. 
4. Visualization of intestinal 13C peptide uptake in vivo 
Transcytosis of the 13C peptide was further verified in a mouse model by confocal microscopy. 
Uptake of 13C-FITC into small intestinal epithelial cells as well as cells within the villi was 
detected as early as 5 min after luminal delivery of the construct (Figure 2 A, B). In contrast, 
very little or no uptake of the control peptide 13Csc-FITC was observed with most of the 
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material being trapped in the mucus of the gut lumen (Figure 2 C, D). Furthermore, CD11c 
positive cells, most likely dendritic cells, located in the villi in close proximity to the epithelium 
were found to be positive for 13C.  
 
Figure 2. Verification of peptide uptake in murine intestinal cells in vivo. Peptides were injected 
into the lumen of the small intestine and incubated for 5 minutes. (A+B) injection of 13C-FITC; 
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(B+C) injection of scrambled control peptide 13Csc-FITC; (E+F) 10 min preincubation with 
13C-peptide before injection of 13C-FITC and 5 min incubation (grey: nuclear stain DAPI; 
green: peptide-FITC construct; blue: CD11c-Alexa Fluor® 647; cyan: overlay of FITC peptide 
and CD11c signal; scale bar: 100 µm; A, C and E show an overlay of all channels with a bright 
field image; B, D and F show an overlay of FITC and Alexa Fluor® 647 signal). 
We conducted 13C uptake studies to reveal if a saturating receptor-ligand interaction is involved.  
Pre-expose of the intestinal mucosa with unlabeled peptide did not block the uptake of labeled 
peptide. The 13C-FITC construct was found inside the villi of the small intestine with a cellular 
distribution and visual fluorescence intensity similar to the previous experiments in which pre-
incubation with unlabeled 13C peptide was omitted (Figure 2 E, F).  
5. Peptide 13C facilitates protein uptake 
Peptide 13C facilitated mucosal transcytosis both as a peptide and when expressed on M13 
phage (size: 7 x 900nm; equivalent to a MW >1x107). We next tested whether the peptide would 
promote the delivery of protein across the mucosal barrier. We used fluorescent streptavidin as a 
model protein which was coupled to biotinylated peptide 13C. In order to visualize the 
transcytosis of 13C-protein and control 13Csc-protein, the biotinylated peptides were coupled to 




Figure 3. Determination of peptide-protein-construct binding and uptake in murine intestinal 
cells in vivo. 13C-streptavidin and control peptide construct (13Csc-streptavidin) were 
simultaneously injected into the intestinal lumen and incubated for 45 minutes. The right panel 
(C,F and I) show the merged images of the 13C-streptavidin (A,D and G) and 13Csc-streptavidin 
(B, E and H) images. (A-F) villous region of the small intestine; (G-I) PP region. (grey: nuclear 
stain DAPI; blue: CD11c-Alexa Fluor® 647; red: 13C-streptavidin-Alexa Fluor® 694; green: 
13Cscrambled-streptavidin-Alexa Fluor® 488; scale bar: 20 µm).  
In line with our previous observations, we detected 13C-streptavidin in distinct epithelial cells 
and in cells within the villi, while the 13Csc-streptavidin control construct could only be 
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observed in the lumen of the gut (Figure 3 G-I, representative images). Strikingly, a distinct 
uptake of 13C-streptavidin construct was also observed in CD11c-positive cells, most likely 
dendritic cells, located in the lamina propria or in PP. To exclude artefacts due to properties of 
the different Alexa dyes, we switched labelling of 13C and 13Csc, using streptavidin Alexa 
Fluor® 488 and Alexa Fluor® 546, respectively, and repeated the experiment. Once again, only 
the 13C coupled protein was detectable inside epithelial cells (data not shown). Therefore, 
peptide 13C facilitated uptake and transportation of a specific protein across the intestinal wall in 
a mouse model.  
6. Determination of systemic delivery of a 13C - protein construct 
We next tested if peptide 13C would improve the delivery of proteins into the systemic 
circulation. Radiolabelled 13C and 13Csc constructs were given either orally, rectally, or nasally. 
Four hours after administration, the fraction of radioactivity in blood cells and blood plasma was 
measured. The background level of total radioactivity in the TCA-soluble plasma fraction ranged 
between 0.4-1.8% (data not shown). 
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Figure 4. Mucosal uptake of peptide-protein-construct and distribution into blood plasma. Mice 
were treated orally (A), rectally (B) or nasally (C) with peptide conjugated to radiolabeled 
(125I)-streptavidin (SA-I125). After four hours, mice were dissected and radioactivity was 
analyzed in various compartments. Graphs show the radioactivity in the blood compartments as 
% of total radioactivity recovered from the mouse. (Mean ± SEM; oral: n=5; rectal: n=9; nasal: 
n=13-15; D’Agostino & Pearson omnibus normality test α=0.05, unpaired t test; * p< 0.05; ** p< 
0.01) 
While a major part of the radioactivity remained at the site of administration (data not shown), a 
small but significant enrichment of intact 13C-conjugate as compared to 13Csc- or streptavidin 
control could be detected in the systemic circulation after rectal and nasal, but not after oral 
administration of the construct (Figure 4 A-C). 13C peptide increased the systemic levels of the 
model protein approximately 2.5- and 1.9-fold after rectal and nasal delivery, respectively. In 
none of the application routes were significant amounts of 13C-streptavidin detected within the 
cellular fraction of the blood, showing that 13C protein is not transported by blood leukocytes. In 
conclusion, peptide 13C facilitated the transportation of the 13C-protein construct into the 
systemic circulation after mucosal administration. 
 
DISCUSSION 
In this study we identified a cyclic peptide that facilitates the rapid transportation of intact 
macromolecules across the mucosal surface into distinct cells of the submucosa as well as into 
the systemic circulation. The peptide was identified in a large animal model by using a 
combination of in vitro and in vivo panning procedures of phage display libraries. The panning 
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was designed to specifically enrich for peptides that facilitated transcytosis across the 
mammalian intestinal epithelium into the intestinal afferent lymphatic system. The selection 
resulted in a small set of peptides that were repeatedly isolated, dominated by the cyclic nonamer 
CTANSSAQC, 13C. 13C was isolated from lymph plasma as well as from cells that traffic in 
afferent lymph.   
Our panning strategy involved the independent selection of both a conformationally constrained 
and a linear phage display library, initially in vitro and then in vivo in a sheep model. These 
preselected libraries were then combined and further selected in vivo in an effort to select for 
phage that were transported into the lymphatic system directly draining from the small intestine. 
Interestingly, these additional panning steps resulted only in the selection of several cyclic 
peptides, suggesting that disulphide-bonded cyclic peptides form superior transcytosis ligands. It 
may be that the disulphide bond stabilizes the peptide and / or makes it more resistant to 
proteolytic degradation and thus is superior in a harsh environment such as the intestine of 
animals.  
We established that the transcytosis of the ligands is not due to non-specific transportation of 
phage across the mucosa27, as the selected transport of library phage was several orders of 
magnitude greater than that of wild-type phage. Furthermore, in contrast to a study in rats where 
single peptides were identified18, we found that several of the transcytosed peptides were 
identified repeatedly, which provides further evidence for specific enrichment. This is supported 
by the fact that we found transcytosis into lymph occurring within 30 min after intestinal 
delivery of selected library phage. Rapid transportation of library phage was previously observed 
in a study in rats in which phage were recovered from tissues such as spleen, liver or kidney soon 
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after injection into the jejunum21. Taken together these results provide strong evidence that our 
panning procedure resulted in the selection of specific transcytosis reagents.  
We next conducted experiments to establish which of the selected peptides would be the most 
effective transcytosis ligand. Three peptides identified in the phage panning were synthesized 
and then inoculated directly into the otherwise unmodified small intestine of sheep. Inoculation 
into the intestine was used to prevent potential degradation in the rumen and abomasum. To 
enable identification in the lymph in ex vivo samples, each of the synthetic peptides was tagged 
with biotin on the amino terminus and radioactively-labelled tyrosine at the carboxyl terminus. 
Detection of intact peptide involved binding to a streptavidin matrix via the biotin tag, followed 
by measurement of the radioactive label. To our knowledge this is the first report of an intact 
peptide that is selectively transcytosed into intestinal lymph from a fully functional small 
intestine. The recovery of significant amounts of synthetic peptides from lymph soon after 
inoculation (peak levels were detected from 30 min to 1 h followed by a constant decline) 
compared to a scrambled control peptide confirmed that preferential transcytosis has occurred. 
We found that peptide 13C outperformed the other two peptides tested. Consequently we used 
13C in follow up mouse studies to confirm the efficacy of the trans-mucosal delivery of proteins 
in a second animal model.  
Initially, we used confocal microscopy to determine if 13C facilitates the delivery of molecules 
into specific cellular compartments of the small intestine. Peptide 13C, when directly labeled to a 
fluorescent dye or when bound to streptavidin, could be detected in a subset of epithelial cells as 
well as specific cells that underlie the epithelium as early as 5 min after delivery into the small 
intestine. These findings demonstrate that peptide 13C facilitates transcytosis and enrichment in 
mouse epithelial cells and cells of the intestinal villi. A subset of the 13C-positive epithelial cells 
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showed goblet cell like morphology and location which indicates that goblet cells might be 
involved in the recognition and uptake of the peptide conjugate. While antigen transport by M 
cells is well established, a recent report showed that goblet cells can perform a similar function 
by taking up antigens from the gut lumen4. We also found that CD11c positive dendritic cells 
located in the intestinal villi and in jejunal PP take up 13C peptide conjugates. It remains to be 
determined if DCs directly sample the material via dendrites that protrude into the lumen of the 
intestine28 or whether the 13C conjugate is presented by epithelial cells. However, a recent report 
that describes the capacity of goblet cells for antigen uptake from the intestinal lumen followed 
by antigen transfer to CD103+ dendritic cells4, in conjunction with our observation, provides 
support that goblet cells present a 13C conjugate to DC. 13C positive cells were also found in 
cells that traffic in afferent lymph. It is therefore likely that uptake by DCs is followed by signals 
that initiate migration.  
Interestingly a phage display study in rats identified a nine amino acid long peptide (CSK; 
CSKSSDYQC) which increased uptake via the intestinal mucosa21. Our peptide 13C and CSK 
share some sequence similarities, notably the presence of a ser-ser motif. The CSK peptide was 
reported to be taken up primarily by goblet cells. This suggests that the two peptides share some 
features, but uptake is likely to involve different mechanisms. In vitro competition experiments 
with CSK peptide suggested a receptor-mediated uptake21, 22, whereas uptake of 13C constructs, 
as far as could be seen using fluorescence imaging, was not blocked by a 20-fold excess of free 
13C peptide. As the scrambled version of 13C peptide is not transcytosed, non-specific uptake 
mechanisms such as pinocytosis are unlikely. One possible explanation is that 13C binds to a low 
affinity, but abundant, receptor which is not saturable and is only present on a subset of epithelial 
cells. 
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We also were able to re-isolate labeled 13C peptide from lymph plasma and consequently 
wanted to establish if 13C could be used to deliver molecules into the systemic circulation. Such 
an enhanced mucosal delivery of molecules into the blood system would be of significant interest 
for treatment with protein-based drugs. We have shown that 13C enhances uptake of 
radiolabeled streptavidin, and the labeled 13C-strepavidin complex could also be found in blood 
plasma. Thus, we investigated if 13C would facilitate the transportation of therapeutic proteins 
into systemic circulation. We found that 13C facilitated transportation of a protein into the 
systemic circulation after intra-rectal as well as intra-nasal delivery but not after oral delivery. It 
is possible that oral delivery of the non-protected target protein has resulted in gastric or 
intestinal degradation. It remains to be determined if the use of acid-resistant capsules or 
nanoparticles would prevent degradation and improve efficient delivery of 13C-coupled 
materials by the oral route.  
In conclusion, this study describes a novel cyclic peptide that has functional characteristics of a 
transport vehicle for biomolecules. It enhances the uptake of proteins through the gut wall, 
promotes systemic delivery as well as accumulation in intestinal epithelial cells and dendritic 
cells. It therefore might find applications for oral, nasal or rectal delivery of biomolecular drugs 
making intravenous application procedures dispensable. Moreover, preferential targeting to 
intestinal cells might be useful therapeutically to deliver immunomodulatory or other agents so 
that they achieve more effective treatment of chronic inflammatory diseases of the gut. Whether 
or not 13C facilitated intestinal transportation enables the development of novel approaches for 
the induction of oral tolerance induction29, or if it could be used to develop tolerogenic 
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